Corbus Pharmaceuticals, Inc.
100 River Ridge Drive
110 articles about Corbus Pharmaceuticals, Inc.
Clinical Catch-Up: October 5-9
10/12/2020It was a moderately busy week for clinical trial news. Here’s a look.
Funds will also be utilized to enhance Corbus’ pipeline of novel endocannabinoid system-targeting drug candidates, and the company’s workforce will be reduced by up to 54%.
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis.
Clinical Catch-Up: September 7-11
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2).
Clinical Catch-Up: August 10-14
8/17/2020It was a very busy week for clinical trial updates. Here’s a look.
BioSpace Movers & Shakers, July 10
7/10/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Clinical Catch-Up: May 31-June 5
6/8/2020As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
BioSpace Movers & Shakers, May 29
5/29/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Clinical Catch-Up: April 27-May 1
5/4/2020There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30%
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and Japan
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
The New York Academy of Sciences symposium will highlight cutting edge research across the fields of inflammation, infection, and tissue regeneration, with focus on novel resolution mediators and mechanisms
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND
Corbus Pharma Announces Agreement With FDA on Phase IIb Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
The Company and the FDA agreed that the event rate of pulmonary exacerbation is an acceptable sole primary efficacy endpoint for the clinical development program to support registration of lenabasum for the treatment of CF.
In less than four years, Corbus has grown from a tiny startup to a public company with 60 employees and four assets in the clinic.
Corbus' stock popped on the release of topline results from a midstage study involving its lead (and only) clinical drug, anabasum.
Corbus Pharmaceuticals Reports Positive Topline Results From Phase 2 Study In Rare Autoimmune Disease Dermatomyositis
Corbus Pharmaceuticals Holdings announced positive topline results from its 16-week Phase II study of safety and efficacy of anabasum in dermatomyositis (“DM”).
Corbus Pharma Appoints Paris Panayiotopoulos To Its Board Of Directors
Corbus Pharmaceuticals, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors.